Cancer pathogenesis is intricately linked to genetic alterations, encompassing somatic mutations, epigenetic modifications, and germline predispositions.  Recent advances in high-throughput sequencing technologies have revolutionized our understanding of the genomic landscape of cancer, revealing the complex interplay of driver and passenger mutations across diverse tumor types.  This wealth of genomic data fuels the development of personalized medicine, enabling targeted therapies matched to specific genetic profiles.  Advances include the identification of actionable mutations driving oncogenesis, facilitating the selection of effective tyrosine kinase inhibitors, immune checkpoint inhibitors, and other targeted agents.  Furthermore, circulating tumor DNA (ctDNA) analysis offers minimally invasive methods for early cancer detection, monitoring treatment response, and identifying emerging resistance mechanisms.  Despite significant progress, challenges remain, including the heterogeneity within tumors, the complexities of interpreting genomic data, and the cost-effectiveness of widespread genomic profiling.  Future research should focus on integrating multi-omics data, developing robust predictive biomarkers, and addressing access and equity issues to fully realize the transformative potential of personalized cancer medicine.